Ideaya Biosciences, Inc. (NASDAQ:IDYA) is a company in the biomedical and genetics industry, focusing on developing innovative therapies for cancer treatment. Despite its promising research, the company faces financial challenges, as seen in its recent earnings report. Competitors in the same industry include companies like Amgen and Gilead Sciences.
On February 18, 2025, Ideaya reported an earnings per share (EPS) of -$1.49, which was significantly below the estimated EPS of -$0.67. This represents a negative surprise of 122.39%, as highlighted by Zacks. The loss per share increased from the previous year's $0.52, indicating growing financial challenges.
Despite the disappointing EPS, Ideaya generated $7 million in revenue, surpassing the estimated $2.5 million. This aligns with the Zacks Consensus Estimate and marks an increase from the $3.92 million reported a year ago. However, the company has not exceeded revenue estimates in the last four quarters.
The company's financial ratios reflect its current struggles. With a negative P/E ratio of -10.16, Ideaya is not profitable. The high price-to-sales ratio of 462.67 and enterprise value to sales ratio of 365.43 suggest the stock is trading at a high price relative to its sales.
Despite these challenges, Ideaya maintains a low debt-to-equity ratio of 0.016, indicating minimal reliance on debt. The strong current ratio of 22.93 shows excellent short-term liquidity, suggesting the company can meet its short-term obligations.
